Advaxis, Inc. (ADXS) Reaches $2.63 52 Week Low; AutoCanada Inc. (TSE:ACQ) Had 2 Bullish Analysts

February 11, 2018 - By Marguerite Chambers

Among 4 analysts covering Autocanada (TSE:ACQ), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Autocanada had 32 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Scotia Capital with “Sector Perform” on Thursday, April 13. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, March 15 report. As per Monday, August 10, the company rating was maintained by Canaccord Genuity. As per Friday, April 28, the company rating was maintained by Scotia Capital. The stock of AutoCanada Inc. (TSE:ACQ) earned “Outperform” rating by RBC Capital Markets on Monday, October 31. The firm has “Sector Perform” rating given on Thursday, February 2 by RBC Capital Markets. The stock has “Sector Perform” rating by Scotia Capital on Friday, March 31. The rating was maintained by Scotia Capital with “Sector Perform” on Wednesday, September 21. The rating was maintained by Scotia Capital on Friday, November 4 with “Sector Perform”. The stock of AutoCanada Inc. (TSE:ACQ) has “Sector Perform” rating given on Friday, March 10 by Scotia Capital. See AutoCanada Inc. (TSE:ACQ) latest ratings:

The stock of Advaxis, Inc. (NASDAQ:ADXS) hit a new 52-week low and has $2.55 target or 3.00% below today’s $2.63 share price. The 7 months bearish chart indicates high risk for the $109.26M company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $2.55 price target is reached, the company will be worth $3.28M less. The stock decreased 2.59% or $0.07 during the last trading session, reaching $2.63. About 1.00 million shares traded or 22.19% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has risen 11.01% since February 11, 2017 and is uptrending. It has underperformed by 5.69% the S&P500.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $109.26 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 8 analyst reports since September 11, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) rating on Thursday, July 6. Cantor Fitzgerald has “Buy” rating and $1900 target. The stock has “Buy” rating by H.C. Wainwright on Wednesday, December 27. The firm has “Buy” rating by Cantor Fitzgerald given on Wednesday, May 31. The rating was maintained by H.C. Wainwright on Wednesday, June 14 with “Buy”. The rating was maintained by H.C. Wainwright on Wednesday, November 8 with “Buy”. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, June 12. Guggenheim initiated the stock with “Buy” rating in Friday, September 11 report. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Overweight” rating by Barclays Capital on Tuesday, September 22.

Investors sentiment decreased to 1.23 in Q3 2017. Its down 0.40, from 1.63 in 2017Q2. It turned negative, as 12 investors sold Advaxis, Inc. shares while 18 reduced holdings. 17 funds opened positions while 20 raised stakes. 16.94 million shares or 12.95% less from 19.46 million shares in 2017Q2 were reported. Northwestern Mutual Wealth Mngmt invested in 5,000 shares. Voya Mngmt Limited Com owns 17,612 shares. State Of Wisconsin Inv Board reported 31,000 shares. Ny State Common Retirement Fund invested in 34,200 shares. Deutsche Bankshares Ag accumulated 35,945 shares or 0% of the stock. Swiss Bancorporation has 55,800 shares for 0% of their portfolio. Tiaa Cref Inv Ltd Liability Company invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Hutchin Hill Cap Limited Partnership reported 67,600 shares. Citigroup invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Dimensional Fund Ltd Partnership invested in 0% or 54,273 shares. D E Shaw & holds 0% or 201,151 shares. 8,774 were reported by Legal & General Group Incorporated Public Ltd. Zacks Inv Mngmt has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). 43,368 were reported by Rhumbline Advisers. Sabby Management Ltd Liability reported 0.01% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS).

Since September 22, 2017, it had 0 insider purchases, and 4 sales for $8.07 million activity. Bonstein Sara sold 5,224 shares worth $16,612. 1.24 million Advaxis, Inc. (NASDAQ:ADXS) shares with value of $5.47M were sold by ADAGE CAPITAL PARTNERS GP – L.L.C.. 32 Advaxis, Inc. (NASDAQ:ADXS) shares with value of $94 were sold by LOMBARDO ANTHONY A.

The stock decreased 0.47% or $0.1 during the last trading session, reaching $21.26. About 35,583 shares traded. AutoCanada Inc. (TSE:ACQ) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.

AutoCanada Inc., through its subsidiaries, operates franchised automobile dealerships in Canada. The company has market cap of $582.29 million. It offers a range of automotive services and products, including new vehicles, used vehicles, parts, and collision repair services; and facilitates the sale of third party finance and insurance products, extended warranties, and replacement and after-market automotive products. It has a 10.73 P/E ratio. The firm sells its new vehicles under the Chrysler, Dodge, Jeep, Ram, Fiat, Chevrolet, GMC, Buick, Cadillac, Hyundai, Kia, Nissan, Infiniti, Volkswagen, Audi, BMW, MINI, Mitsubishi, and Subaru brands.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>